Inventiva S.A. (ETR:6IV)
Germany · Delayed Price · Currency is EUR | Market Cap | 837.68M +217.8% |
| Revenue (ttm) | 7.93M -43.8% |
| Net Income | -354.14M |
| EPS | -1.90 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,958 |
| Average Volume | 1,264 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 3.145 - 6.280 |
| Beta | n/a |
| RSI | 34.02 |
| Earnings Date | Mar 30, 2026 |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th... [Read more]
Financial Performance
In 2025, Inventiva's revenue was 7.93 million, a decrease of -43.76% compared to the previous year's 14.09 million. Losses were -354.14 million, 92.2% more than in 2024.
Financial StatementsNews
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial ...
Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial Stability Amidst Challenges
Full Year 2025 Inventiva SA Earnings Call Transcript
Full Year 2025 Inventiva SA Earnings Call Transcript
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures rise on Tuesday with Dow futures up 400 points. Phreesia shares fall 26.5% in pre-market after mixed Q4 results and lower sales guidance. Other stocks also ... Full story available ...
Inventiva reports 2025 full year results and provides a business update
Daix (France), New York City (New York, United States), March 30, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Truist Securities Initiates Coverage on Inventiva (IVA) with a "Buy" Rating | IVA ...
Truist Securities Initiates Coverage on Inventiva (IVA) with a "Buy" Rating | IVA Stock News
Inventiva reports preliminary 2025¹ fiscal year financial results
Daix (France), New York City (New York, United States) , February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focus...
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the develop...
Biotech Inventiva's 50% surge shows investor optimism over liver disease drug
A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for betting on the loss-making French biotech, which is on the verge of entering the fast-grow...
Inventiva reports 2025 Third Quarter Financial Information¹
Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focus...
Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces launch of public offering
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Daix (France), New York City (New York, United States), October 7, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
Daix (France), New York City (New York, United States), September 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...
Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings
Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept.
Inventiva to Host Analyst and Investor Event on October 8, 2025
Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...